CARDIOVASCULAR SCIENCES, INC. Surpasses Expectations in Research to Develop Anti-adhesion Material
ORLANDO, FLORIDA (March 19, 2007) Cardiovascular Sciences, Inc. has completed its initial phase of funded research at the University of Central Florida to develop a post-surgical anti-adhesion material. Adhesive scar tissue forms as a result of any surgical procedure and often creates pain and other complications for patients. The adhesions can impair healing, restrict movement, and make further surgical procedures difficult or unfeasible.
Cardiovascular Sciences’ research is targeted at developing a material that can be applied internally during surgery to almost completely prevent adhesive tissue formation. The Company’s sponsored research is being conducted with the Chemistry Department at UCF and led by Dr. Kevin Belfield, PhD. Initial results have exceeded expectations both in terms of time for development and in the physical characteristics of the material.
Cardiovascular now has several prototypes of their proprietary anti-adhesion material and the technology to manipulate its properties. The company is ready to move ahead with expanded animal studies and further investigate safety and efficacy of the product. The first product should be market-ready 18 to 24 months after initiation of expanded animal studies.
The initial target market is in the veterinary field with a market potential for anti-adhesion applications of $250 million in the United States alone. Applications and products for the human market will be addressed following successful applications in the veterinary field.
Cardiovascular Sciences joined the UCF Technology Incubator a year ago and is housed in the Incubator’s Central Florida Research Park facilities. Dr. Lawrence Hooper, Director of Clinical and Regulatory Affairs stated, “The Incubator is the principle factor that has allowed us to progress this far and at this rate. Our participation in the program removes a lot of the usual worries and stress so that we can more fully concentrate on those issues and problems specific to our field of endeavor.”
For more information, contact:
Dr. Lawrence H. Hooper, Cardiovascular Sciences, 407-208-9943
Tom O’Neal or Carol Ann Dykes, UCFTI, 407-882-0202
Larry Vershel or Beth Payan, LV Communications Inc. 407.644.4142.
About Cardiovascular Sciences, Inc.
Based in Orlando, Florida, Cardiovascular Sciences Inc. is a technology
company focused on the development of innovative medical products. Cardiovascular
Sciences is currently developing proprietary technology for the prevention
of post-surgical adhesions. Adhesions are fibrous scar tissue formations
that develop between tissues or organs following trauma, or the “insult” to
tissues and organs associated with virtually any surgical procedure. The
currently available techniques, methods, and products used in treatment
of these applications are usually no more than 50% effective. Cardiovascular
Sciences’ novel anti-adhesion products are being developed to be
more effective, easier to handle, and much less costly than those currently
on the market. For more information, visit www.cvsciences.org.
About the UCF Technology Incubator
Since its founding in 1999, the UCF Technology Incubator has helped more than 80 emerging technology companies create over $200 million in annual revenues and more than 700 new jobs with an average salary of $59,000. As a result of this success, the UCF Technology Incubator was named the 2004 Technology Incubator of the Year by the National Business Incubation Association. Headquartered in Research Park near the University, the Incubator is a true collaboration in economic development between UCF, Orange County, the City of Orlando, Seminole County, the Florida High Tech Corridor Council and the Metro Orlando Economic Development Commission. For more information, please visit www.incubator.ucf.edu.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular when used in the preceding discussion, the words “believes”, “expects”, “intends”, “will”, “anticipated” or “may” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties including, without limitation, risks associated with operations, availability of capital on a reasonable term, the effects of government regulations and operations risks.
